Jazz Pharmaceuticals (JAZZ) Operating Income (2010 - 2026)

Jazz Pharmaceuticals' Operating Income history runs 17 years deep, the most recent figure standing at $336.6 million for Q1 2026.

• In Q1 2026, Operating Income rose 702.15% year-over-year to $336.6 million; the TTM figure through Mar 2026 stood at -$37.7 million (down 106.35% YoY), while the FY2025 annual figure was -$430.2 million, down 160.04% from the prior year.
• Operating Income for Q1 2026 stood at $336.6 million, up from $254.5 million in the prior quarter.
• The five-year high for Operating Income was $336.6 million in Q1 2026, with the low at -$686.4 million in Q2 2025.
• The 5-year median for Operating Income is $122.5 million (2023), against an average of $66.8 million.
• The sharpest annual moves came in 2022 and 2026: Operating Income tumbled 633.39% in 2022, then surged 702.15% in 2026.
• Jazz Pharmaceuticals' Operating Income stood at -$263.4 million in 2022, then jumped by 146.51% to $122.5 million in 2023, then surged by 55.73% to $190.8 million in 2024, then soared by 33.43% to $254.5 million in 2025, then jumped by 32.24% to $336.6 million in 2026.
• Business Quant data shows JAZZ's Operating Income at $336.6 million in Q1 2026, $254.5 million in Q4 2025, and $57.5 million in Q3 2025.